OncologyEducation presents MedOncNow
In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.
21 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der OncologyEducation presents MedOncNow-Community!